AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?
CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.
That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.
Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.
Get unlimited access to award-winning journalism and exclusive events.
